Health Management Training to Enhance Influenza Vaccine Immunogenicity

NCT ID: NCT01256515

Last Updated: 2013-05-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to assess the immunogenicity of inactivated influenza vaccination (IIV) in healthy elderly volunteers aged 50 years and older receiving one of two different health management trainings.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We will obtain preliminary data on the time it takes to achieve a protective immune response, durability of response and occurrence of influenza in the following influenza season. Promising results in this age group will provide preliminary data for expanded future studies in the elderly.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

No Conditions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Health Education Training Group 1

One form of health education training

Group Type EXPERIMENTAL

Health Education

Intervention Type BEHAVIORAL

CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.

Health Education Training

Intervention Type BEHAVIORAL

8 weeks of group training regarding health education techniques.

Health Education Training Group 2

Another form of health education training

Group Type ACTIVE_COMPARATOR

Health Education

Intervention Type BEHAVIORAL

CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.

Health Education Training

Intervention Type BEHAVIORAL

8 weeks of group training regarding health education techniques.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Health Education

CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.

Intervention Type BEHAVIORAL

Health Education Training

8 weeks of group training regarding health education techniques.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 50 years or older
* Infectious Disease tests - negative HIV test; hepatitis B surface antigen; anti-hepatitis C virus (HCV)
* Routine Laboratory tests
* able and willing to complete the informed consent process
* able and willing to participate for the planned duration of the study, including availability for follow-up telephone contact

Exclusion Criteria

* self report of any medical conditions for which the Center for Disease Control (CDC) states should not be vaccinated with IIV
* self-reported vaccination with the seasonal influenza vaccine for the current 2010-2011 influenza season (vaccination with the H1N1 influenza vaccine before, during, or after the study will not be exclusionary)
* history of hypersensitivity to any influenza vaccine components including thimerosal or egg
* history of Guillain-Barre syndrome
* self-reported treatment with immunomodulator/immunosuppressive drugs (interleukins (IL), corticosteroids (oral or inhaled)), G(M)- cerebrospinal fluid (CSF)) in 4 weeks before enrollment or self reported history of IL-2 administration within 5 years
* self-reported use of theophylline preparations or warfarin because of the theoretical possibilities of enhanced drug effects and toxicities following influenza vaccination
* any clinically significant abnormalities found during a routine physical examination
* self-reported history of any autoimmune disease
* acute febrile illness on the day of intended immunization - immunization deferred until illness resolved
* self report of current alcohol, substance abuse, or systemic/psychiatric illness that potentially could interfere with compliance and ability to make study visits (such as severe attention deficit hyperactivity disorder (ADHD) and current major depressive episode)
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centers for Disease Control and Prevention

FED

Sponsor Role collaborator

Massachusetts General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

John W. Denninger, MD, PhD

Director of Research, Benson-Henry Institute

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John Denninger, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Benson-Henry Institute, 151 Merrimac St, 4th Floor

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

5R01DP000339

Identifier Type: NIH

Identifier Source: secondary_id

View Link

2009P001437

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Age and Response to Flu Vaccines
NCT03328325 COMPLETED PHASE4
Inactivated Influenza A/H5N1 Vaccine in the Elderly
NCT00230750 COMPLETED PHASE1/PHASE2
H5N1 Vaccine Study in Japanese Adults
NCT01382329 COMPLETED PHASE2/PHASE3